Global Market Digital Biomarkers is Anticipated to grow at a Significant Pace i.e., USD 5,937.4 Million during the Forecast Period 2021-2027

Published Date: Oct, 2021

The global digital biomarkers market is expected to witness a CAGR of 41.25% during the forecast period. The growth of digital biomarkers is attributed to the rapid adoption of smartphones, wearable devices, biosensors, and innovation of high-speed networks, and connectivity solutions.  The increasing cases of diabetes, BP, cardiovascular diseases, neurological disorders will propel the growth of the digital biosensors market globally as it is used for monitoring, diagnostic and prognostic purposes. Furthermore, the rising number of synergistic associations among stakeholders, R&D of the advanced digital markers, increasing number of industry players, favorable government initiatives, fast approval from FDA, multiple product launches, are significantly aiding the growth of the global digital biomarkers market. Moreover, the data generated from biomarkers are validated via clinical trial programs.  Nevertheless, the rising application of digital biomarkers to diagnose various neurological disorders like Alzheimer, Parkinson, etc. will create opportunities for the growth of the digital biomarkers during the forecast period 2021-2027. Thus, diagnostic biomarkers will create opportunities in the future of medicine and will provide personalized treatment to patients.

Digital solutions for biomarkers is the modernized platform to generate, collect and track healthcare data. Healthcare professionals are using the digital biomarkers to facilitate the successful screening and diagnosis of COVID-19 patients remotely.

Browse 73 market data Tables and 47 Figures spread through 280 Pages and in-depth TOC on " Digital Biomarkers Market by System Component (Data Collection Tools (Digital Platforms, Mobile Apps, Desktop-Based Software, Wearable, and Biosensors) and Data Integration Systems), by Therapeutic Area (Cardiovascular Diseases, Neurodegenerative Disorders, Sleep and Movement Diseases, Psychiatric Disorders, Chronic Pain, Gastrointestinal Diseases, Diabetes, Respiratory Diseases, and Others), by Application (Wellness, Disease Diagnosis, Personalized Medication, and Drug Discovery and Development), by Development Status (Novel Digital Biomarkers, Original Digital Biomarkers, and Approved Digital Biomarkers), by End-User (Pharmaceutical Companies & Labs, Healthcare Providers, and Insurance Payers), and Region - Global Forecast to 2027"

By system component, biosensors will hold a significant share in the global digital biomarker market during the forecast period.

Based on the system components, the global digital biomarkers are segmented into data collection tools and data integration systems. The data collection tools are further segmented into digital platforms, mobile apps, desktop-based software, wearable, and biosensors. Moreover, biosensors also hold a significant share in the digital biosensors market owing to its ability to check the health status, onset, and development of diseases and monitors health condition by using a non-invasive approach in medical research.

Global Digital Biomarkers Market Segmentation Analysis

Segment

Categorization

Leading Category

System Component

Data Collection Tools (Digital Platforms, Mobile Apps, Desktop-Based Software, Wearable, and Biosensors) and Data Integration Systems

Data Collection Tools  (Fastest)

Therapeutic Area

Cardiovascular Diseases, Neurodegenerative Disorders, Sleep and Movement Diseases, Psychiatric Disorders, Chronic Pain, Gastrointestinal Diseases, Diabetes, Respiratory Diseases, and Others

Cardiovascular Diseases (Largest)

Chronic Pain (Fastest)

Application

Wellness, Disease Diagnosis, Personalized Medication, and Drug Discovery and Development

Drug Discovery and Development (Significant)

Development Status

Novel Digital Biomarkers, Original Digital Biomarkers, and Approved Digital Biomarkers

Approved Digital Biomarkers (Largest)

End-User

Pharmaceutical Companies & Labs, Healthcare Providers, and Insurance Payers

Pharmaceutical Companies (Highest)

Region

North America, Europe, Asia-Pacific, and Rest of the World

North America (Largest)
Europe (High CAGR)

Asia-Pacific (Fastest)

Discover More About This Report, Download A Free Sample Copy of Global Digital Biomarkers Market

“Europe is witness to hold high CAGR during the forecast period.”

Europe is anticipated to have a high CAGR during the forecast period 2021-2027 owing to the rising standardization and collaboration among the stakeholders in the pharmaceutical industry. Moreover, the rising adoption of telehealth services, strong healthcare infrastructure, and rise in spending by the government for development in medical research will fuel the growth in the region.

Some of the major players in the global digital biomarkers market include AliveCor Labs, Eli Lilly and Company, Biogen, Novartis AG, Fitbit LLC, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Scope of the Report

Report Metric

Details

Market Size Available for the Years in the Study

2015–2027

Historical Period

2015–2020

Base Year

2020

Forecast Period

2021–2027

Segments Covered in the Study

 System Component, Therapeutic Area, Application, Development Status, End-User, and Region

Geographies Covered in the Study

North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Russia), Asia-Pacific (China, Japan, India, South Korea), and Rest of the World (Brazil, Saudi Arabia, South Africa, U.A.E.)

Companies Covered in the Study

AliveCor Labs, Eli Lilly and Company, Biogen, Novartis AG, Fitbit LLC, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Pfizer Inc., and Takeda Pharmaceutical Company Limited

Global Digital Biomarkers Market Coverage

System Component Insight and Forecast 2015-2027

  • Data Collection Tools
    • Digital Platforms
    • Mobile Apps
    • Desktop-Based Software
    • Wearable
    • Biosensors
  • Data Integration Systems

Therapeutic Area Insight and Forecast 2015-2027

  • Cardiovascular Diseases
  • Neurodegenerative Disorders
  • Sleep and Movement Diseases
  • Psychiatric Disorders
  • Chronic Pain
  • Gastrointestinal Diseases
  • Diabetes
  • Respiratory Diseases
  • Others

Application Insight and Forecast 2015-2027

  • Wellness
  • Disease Diagnosis
  • Personalized Medication
  • Drug Discovery and Development

Development Status Insight and Forecast 2015-2027

  • Novel Digital Biomarkers
  • Original Digital Biomarkers
  • Approved Digital Biomarkers

End-User Insight and Forecast 2015-2027

  • Pharmaceutical Companies & Labs
  • Healthcare Providers
  • Insurance Payers

Geographical Segmentation

Digital Biomarkers Market by Region

North America

  • By System Component
  • By Therapeutic Area
  • By Application
  • By Development Status
  • By End-User
  • By Country – U.S., Canada, and Mexico

Europe

  • By System Component
  • By Therapeutic Area
  • By Application
  • By Development Status
  • By End-User
  • By Country – Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe

Asia-Pacific (APAC)

  • By System Component
  • By Therapeutic Area
  • By Application
  • By Development Status
  • By End-User
  • By Country – China, Japan, India, South Korea, and Rest of Asia-Pacific

Rest of the World (RoW)

  • By System Component
  • By Therapeutic Area
  • By Application
  • By Development Status
  • By End-User
  • By Country – Brazil, Saudi Arabia, South Africa, U.A.E., and Other Countries

 

 

Our Industry
Global Market Digital Biomarkers is Anticipated to grow at a Significant Pace i.e., USD 5,937.4 Million during the Forecast Period 2021-2027